Financial & Business News

The Blackwell ramp leads the narrative. GB300 is in volume production at a rate of 1,000/week. Q3 revenue was projected at a growth rate of +54% yoy. Guided FQ3 gross margin at 73.3%–73.5%. A 15% H20 China arrangement could unlock $2–$5B Q3 shipments, and the outlook excludes H20 to China. $650M H20 already sold outside China. Rubin (Vera CPU, Rubin GPU, CX9, NVLink 144, Spectrum-X, silicon photonics) is in final pre-production at TSMC; on schedule for volume next year, with mass production targeted for H2 2026.

Chemotherapy-free combination regimen ushers in new era for first-line treatment, with overall survival projected to exceed four years, surpassing monotherapy TKI osimertinib by more than one year RARITAN, N.J. , Sept. 7, 2025 /PR Newswire/ – Johnson & Johnson (NYSE: JNJ) today announced The New England Journal of Medicine (NEJM) published results from the Phase 3 MARIPOSA study, which showed RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE® (lazertinib) demonstrated a statistically significant and clinically meaningful overall survival (OS) improvement for patients with previously untreated (first-line) locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions (ex19del) or L858R substitution mutations.1 The article is available with free access here for a limited time.

Investors can find success in the stock market by sticking with companies that consistently report strong growth in revenues. This is a simple strategy that, when applied across a diversified portfolio of growth stocks, can lead to outstanding returns over a decade or more.

IDACORP offers low beta, strong long-term growth, and a 3% dividend yield, making it a standout in the energy sector. Idaho's economic and population growth, plus IDACORP's monopoly position and $4B capex plan, drive future earnings potential. Despite recent underperformance and share dilution, valuation remains attractive with a 12% upside and projected 3.1% dividend yield.

Petrobras offers a compelling investment case due to its industry-leading margins, low breakeven costs, and robust financial health, even in volatile oil markets. Despite higher CAPEX and political risks, Petrobras remains undervalued, with a strong dividend yield and resilient cash flows supporting a Buy rating. The company's state ownership brings both advantages (favorable financing, strategic importance) and risks (political interference, lower valuation), but long-term prospects remain attractive.

Vital Farms is capitalizing on the growing demand for natural, ethical, and sustainable food, driving strong brand loyalty and premium pricing. Disciplined growth, robust financials, and ample cash allow for expansion without debt, supporting management's ambitious revenue targets through 2027. Despite a premium valuation, consistent earnings beats and operational execution justify a Buy rating, with further upside likely as growth continues.

Oil demand fears and rising U.S. stockpiles pressure crude futures. Unless OPEC+ holds output steady, the forecast points to further price weakness.

OTTAWA—Nearly all of Air Canada's 10,000 flight attendants rejected the tentative deal struck by their union and the carrier last month that ended a nearly four-day shutdown at the country's largest airline.

Explore the exciting world of Johnson & Johnson (JNJ -0.31%) with our contributing expert analysts in this Motley Fool Scoreboard episode. Check out the video below to gain valuable insights into market trends and potential investment opportunities!

NEW YORK, Sept. 07, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Centene Corporation (NYSE: CNC) between December 12, 2024 and June 30, 2025, both dates inclusive (the “Class Period”), of the important September 8, 2025 lead plaintiff deadline.